Recurrent Vulvovaginal Candidiasis Clinical Trial
Official title:
A Prospective, Case-controlled Randomized Study of Human Reproductive Tract Active Lactobacillus in Adjuvant Treatment of Recurrent Vulvovaginal Candidiasis.
We are trying to determine if Clotrimazole vaginal tablets with oral Lactobacillus is better than Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis
Status | Recruiting |
Enrollment | 140 |
Est. completion date | December 30, 2023 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 52 Years |
Eligibility | Inclusion Criteria: - Women be at least 18 years of age - Have symptoms of vulva irritation and or abnormal discharge - Meet the clinical criteria for RVVC - Willing to participate in research Exclusion Criteria: 1. Taking / injecting antibiotics in the past two weeks; 2. A woman who intends to be pregnant, pregnant or lactating; 3. Long term use of contraceptives and immunosuppressants; 4. Postmenopausal; 5. There was no same fixed sexual partner (RSP) before and after treatment 6. Patients with severe gastrointestinal diseases, including colorectal cancer, IBS, IBD, chronic or acute diarrhea, long-term constipation, etc., or receiving gastrointestinal surgery and abdominal surgery within one year, such as cholecystectomy; 7. Patients with severe heart, liver and kidney dysfunction, mental diseases, infectious diseases, tumors, severe anemia, and severe autoimmune diseases (such as rheumatoid arthritis, lupus erythematosus, etc.) |
Country | Name | City | State |
---|---|---|---|
China | Dept Obstetrics and Gynecology | Shenzhen | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Peking University Shenzhen Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The cure rate of RVVC, | The cure rate of RVVC, | 6 months | |
Secondary | Recurrence of RVVC | Recurrence of RVVC | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05074602 -
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
|
Phase 3 | |
Completed |
NCT04029116 -
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
|
Phase 3 | |
Active, not recruiting |
NCT04734405 -
A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)
|
Phase 2/Phase 3 | |
Completed |
NCT01067131 -
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
|
Phase 1 | |
Completed |
NCT03840616 -
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
|
Phase 3 | |
Not yet recruiting |
NCT04639544 -
Effect of a Lactobacillus Strain on the Prevention of Recurrent Vaginal Candidiasis
|
N/A | |
Completed |
NCT02267382 -
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
|
Phase 2 | |
Recruiting |
NCT06190509 -
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
|
Phase 1/Phase 2 | |
Completed |
NCT03561701 -
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
|
Phase 3 | |
Completed |
NCT03562156 -
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
|
Phase 3 | |
Completed |
NCT05795491 -
Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis
|
N/A | |
Completed |
NCT03059992 -
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
|
Phase 3 |